Pantoprazol Stada (Pantoprazole Sodium Sesquihydrate)

Pantoprazole sodium sesquihydrate, the active ingredient in Pantoprazol Stada, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is prescribed for conditions such as gastro‑esophageal reflux disease, erosive esophagitis, Zollinger‑Ellison syndrome, and for preventing NSAID‑induced gastric ulcers.

GNH USA supplies Pantoprazol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality across global markets, and timely delivery.

Pantoprazol Stada, a proton pump inhibitor, is used to manage disorders related to excess gastric acid. - Gastro‑esophageal reflux disease (GERD): alleviates heartburn and esophageal irritation. - Erosive esophagitis: promotes healing of acid‑induced esophageal lesions. - Zollinger‑Ellison syndrome: controls hypergastrinemia‑driven acid hypersecretion. - Prevention of NSAID‑induced gastric ulcers: reduces risk of ulcer formation in patients taking non‑steroidal anti‑inflammatory drugs.

Pantoprazol Stada may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Diarrhea: loose, watery stools occurring intermittently. - Nausea: feeling of unease and urge to vomit. - Abdominal pain: discomfort or cramping in the stomach area.

Serious or Rare Side Effects: - Acute interstitial nephritis: inflammation of kidney interstitium that may impair renal function. - Clostridioides difficile infection: severe colitis caused by bacterial overgrowth. - Severe allergic reactions (anaphylaxis, Stevens‑Johnson syndrome): potentially life‑threatening hypersensitivity requiring immediate medical attention.

When prescribing Pantoprazol Stada, clinicians should consider several precautionary measures to ensure safe use. - Assess renal function: adjust use in patients with severe renal impairment. - Monitor magnesium levels: prolonged therapy may lead to hypomagnesemia. - Evaluate for Helicobacter pylori infection: consider eradication therapy before long‑term use. - Use the lowest effective dose: limit duration to the shortest period necessary. - Avoid concomitant use with drugs that require gastric acidity for absorption unless clinically justified. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Pantoprazol Stada can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole (and other antifungal agents requiring acidic pH): reduced absorption and efficacy. - Atazanavir: decreased plasma concentrations, risking therapeutic failure. - Clopidogrel: diminished activation leading to reduced antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters regularly. - Digoxin: increased serum levels; observe for signs of toxicity. - High‑dose methotrexate: reduced renal clearance; monitor methotrexate concentrations and renal function.